---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-077354"
form_type: "8-K"
ticker: "DFTX"
cik: "0001813814"
company_name: "Definium Therapeutics, Inc."
filed_at: "2026-06-24T21:14:45+00:00"
generated_at: "2026-06-24T21:16:23.379842+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Definium Therapeutics prices $805M public offering of 20.6M shares at $34 each, upsized from $700M

## Summary
- Offering of 20,588,236 common shares at $34.00 per share, with full exercise of underwriters' 30-day option for additional 3,088,235 shares.
- Gross proceeds ~$805M; net proceeds ~$758M after underwriting discounts and expenses.
- Proceeds to fund R&D, commercialization preparation for DT120 ODT if approved, and working capital.
- Underwriters: J.P. Morgan, Jefferies, Leerink, BofA, Evercore ISI, Stifel, Oppenheimer, LifeSci.
- Expected close June 25, 2026; 60-day lock-up for directors, officers, and company.

## SEC filing metadata
- accession: 0001104659-26-077354
- form_type: 8-K
- ticker: DFTX
- cik: 0001813814
- company_name: Definium Therapeutics, Inc.
- filed_at: 2026-06-24T21:14:45+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1813814/000110465926077354/0001104659-26-077354-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1813814/000110465926077354/tm2618395d3_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-077354
- JSON: https://secwatch.observer/filing/0001104659-26-077354.json
- Plain text: https://secwatch.observer/filing/0001104659-26-077354.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.